近期上海证券交易所公布了第三届科技创新咨询委员会委员候选人名单。南都N视频记者获悉，智元机器人联合 创始人兼CTO彭志辉，宇树科技创始人、CEO兼CTO王兴兴，银河通用创始人兼CTO王鹤，强脑科技创始人兼 CEO韩璧丞等知名机器人或AI科技公司高管在列。 据悉，上交所根据《上海证券交易所科技创新咨询委员会工作规则》，上海证券交易所启动了科技创新咨询委员 会（以下简称咨询委）换届工作。经相关单位推荐、履行相关程序，形成第三届咨询委委员候选人名单并进行公 示，公示期为5个工作日。 根据公示名单，新一届科技创新咨询委员会委员候选人共有60人，有来自国家部委机关、高校、研究院的人士， 也有来自上市公司、非上市科技公司方面的高管，还有来自投资机构的高管。 中微公司（688012.SH）董事长兼总经理尹志尧，恒瑞医药（600276.SH）董事、执行副总裁张连山，北京百度网 讯科技有限公司首席技术官王海峰等，第一届和第二届均为委员，第三届继续被聘任。 | 序号 | 姓名 | 工作单位 | 职务 | | --- | --- | --- | --- | | 29 | 何小龙 | 华润微电子有限公司 | 党委书记、董事长 | | ...

Core Viewpoint - The Chinese innovative drug sector has shown remarkable performance in the capital market this year, driven by record-high business development (BD) amounts for overseas expansion and a rapid growth in domestic revenue, indicating a shift from a "cash-burning" model to a "cash cow" model [1][2]. Group 1: Domestic Demand - The demand for high-quality innovative drugs in China is continuously being released, with A-share innovative drug companies achieving a revenue of 28.69 billion yuan in the first half of the year, a year-on-year increase of approximately 42% [2]. - Leading companies like Heng Rui Medicine reported a 14.5% increase in innovative drug sales revenue to 7.57 billion yuan, primarily from the domestic market [2]. - Other companies such as Bai Jie Shen Zhou and Yi Fan Medicine also reported significant revenue growth, with Bai Jie Shen Zhou's flagship product achieving a 36.5% increase in sales [3]. Group 2: Policy Support - The Chinese government has been actively supporting the development of innovative drugs, with 149 innovative drugs included in the national medical insurance directory since 2018 [4]. - The National Healthcare Security Administration has indicated that by May 2025, the cumulative payment for negotiated drugs will reach 410 billion yuan, driving related drug sales to exceed 600 billion yuan [4]. - New policies are being introduced to address pricing and reimbursement challenges for innovative drugs, including the establishment of a commercial health insurance directory for innovative drugs [5]. Group 3: Research and Development Investment - Despite revenue growth, many innovative drug companies are increasing their R&D investments, creating a positive cycle of revenue growth leading to increased R&D and a rich pipeline [7]. - Heng Rui Medicine invested 3.87 billion yuan in R&D, with over 100 innovative products in clinical development [7]. - The overall trend indicates that companies are focusing on building a robust pipeline to sustain future revenue growth [7]. Group 4: Global Positioning - China currently holds nearly 30% of the global drug R&D market share, with a significant number of first-in-class drug pipelines [8]. - The country has become an important source of global pharmaceutical innovation, with a notable increase in technology licensing and overseas expansion [8]. - The past years of investment during the "innovation drug bubble" period are expected to yield significant results in the coming years [8].

公司报告 | 半年报点评 恒瑞医药（600276） 证券研究报告 公司持续降本增效，提升运营效率 2025H1，公司销售费用为 43.89 亿元，销售费用率为 27.85%，同比下降 1.11 pct；管理费用为 12.85 亿元，管理费用率为 8.15%，同比下降 0.48 pct；研 发费用为 32.38 亿元，研发费用率为 20.48%，同比下降 1.85 pct。 海外授权收入持续增长，2025 年至今授权首付款达 7 亿美元 自 2018 年以来，公司与全球合作伙伴进行了 17 笔对外许可交易，潜在总 交易额约为 260 亿美元，首付款总额超 10 亿美元，另获得若干合作伙伴的 股权。其中 2025 年至今，公司已实现 4 笔对外授权，其中最为瞩目的是， 公司将 HRS-9821 项目的海外独家权利以及至多 11 个项目的海外独家许可 的独家选择权授予 GSK，首付款为 5 亿美元，潜在交易总额为 120 亿美元。 创新药收入未来三年或加速增长，新上市项目逐年增多 2025H1 创新药进入快速放量阶段，国际化贡献利润持续增长 事件：公司发布 2025 年上半年业绩公告。2025 年上半年，公司实现营 ...

Core Insights - The Chinese innovative drug sector has shown remarkable performance in the capital market this year, driven by record-high business development (BD) amounts for overseas expansion and a rapid growth in domestic revenue, indicating a shift from a "cash-burning" model to a "cash cow" model [1][2] Domestic Demand - There is a strong and growing domestic demand for high-quality innovative drugs, with A-share innovative drug companies achieving a revenue of 28.69 billion yuan in the first half of the year, a year-on-year increase of approximately 42%, while H-share companies reported 42.13 billion yuan, up about 10% [2] - Leading companies like Heng Rui Medicine reported a 14.5% increase in innovative drug sales revenue to 7.57 billion yuan, primarily from the domestic market, with several drugs contributing to this growth due to expanded indications [2][3] Revenue Growth and Market Dynamics - Innovative drugs from companies like Bai Jie Shen Zhou and Yi Fan Medicine have seen significant sales growth, with Bai Jie Shen Zhou's flagship product achieving 1.19 billion yuan in sales, a 36.5% increase, and Yi Fan's products growing by 169.57% [3] - The Chinese innovative drug industry is in a rapid development phase, benefiting from both domestic insurance market expansion and overseas market opportunities, leading to a trend towards profitability [3] Policy Support - The Chinese government has been actively supporting the development of innovative drugs, with 149 innovative drugs included in the national insurance catalog since 2018, significantly improving the accessibility of new and effective medications [4] - Companies like Jingxin Pharmaceutical and Bei Da Pharmaceutical have reported early signs of revenue growth from drugs that have recently been included in the insurance catalog, demonstrating the positive impact of policy support [4] Future Outlook - The year 2025 is anticipated to be a turning point for revenue growth among innovative drug companies, with 80% of A-share and H-share companies expected to see significant revenue increases following insurance negotiations [5] - The introduction of a commercial health insurance catalog for innovative drugs is expected to alleviate the financial burden on patients and enhance the market for innovative drugs [5][6] R&D Investment - Despite revenue growth, many innovative drug companies are increasing their R&D investments, creating a positive cycle of revenue growth leading to increased R&D and a rich pipeline of future products [7] - Companies like Heng Rui Medicine and Bai Jie Shen Zhou are significantly investing in R&D, with Heng Rui reporting 3.87 billion yuan in R&D spending and over 100 innovative products in clinical development [7] Global Positioning - China is becoming a significant player in global drug development, holding nearly 30% of the global market share, with a notable number of first-in-class drug pipelines and technology licensing agreements [8] - The past years of investment in innovative drug development are expected to yield substantial results around 2025, although caution is advised regarding potential future investment slowdowns [8]

Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" (maintained) [2] Core Insights - The biotech sector in China is experiencing stable revenue growth, with a significant reduction in net losses. In the first half of 2025, 32 Chinese biotech companies achieved revenue of 46.356 billion yuan, a year-on-year increase of 17.97%. Leading biotech firms have diversified product lines and international expansion, while some smaller companies are rapidly growing due to their core products [6][16] - There is a notable trend of Chinese innovative drug assets entering global markets, with the total amount of business development (BD) transactions reaching new records. The upfront payments and total transaction amounts for Chinese innovative drug assets have surged from 8.7/99.4 billion USD in 2020 to 49.4/561.2 billion USD in 2024. In the first half of 2025, the total transaction amount reached 63.55 billion USD, surpassing the total for 2024 and accounting for approximately 40% of global license-out transactions [7][24] - The report suggests focusing on investment opportunities in seven major innovative drug sectors over the next 6-12 months, including next-generation immuno-oncology, weight loss, and small nucleic acids, which are expected to see significant developments [9] Summary by Sections Biotech Revenue and Profitability - In the first half of 2025, the net loss of Chinese biotech companies narrowed significantly, with a total net loss of 1.755 billion yuan, a 50.34% reduction compared to the first half of 2024. Notably, companies like BeiGene turned a profit with a net income of 450 million yuan, marking its first profitable period [18][20] International Expansion of Chinese Innovative Drugs - The total amount of transactions involving multinational corporations (MNCs) purchasing Chinese assets has approached 100 billion USD from 2020 to the first half of 2025, with approximately 11 billion USD in upfront payments. Major companies like BMS, AZ, Merck, and Novartis have been particularly active in acquiring Chinese assets [8][27] Investment Recommendations - Recommended stocks include major pharmaceutical and biotech companies such as Hengrui Medicine, Innovent Biologics, and others across various sectors including traditional Chinese medicine, raw materials, medical devices, and healthcare services [10]

Group 1 - The Shanghai Stock Exchange has announced the candidate list for the third Technology Innovation Advisory Committee, which includes 60 candidates, the highest number to date [2][4] - Wang Xingxing, founder, CEO, and CTO of Yushu Technology, is among the candidates, indicating the company's potential involvement in the advisory committee [2][3] - The committee consists of experts and executives from various sectors, including government agencies, universities, research institutes, listed companies, and investment firms [2][4] Group 2 - The third committee's candidate list includes notable figures such as Yin Zhiyao, chairman and general manager of Zhongwei Company, and Zhang Lianshan, board director and executive vice president of Hengrui Medicine, who may serve for a third consecutive term [3][4] - Yushu Technology is preparing to submit its IPO application to the stock exchange between October and December 2025, with a high probability of listing on the Sci-Tech Innovation Board [4] - The advisory committee's rules stipulate that members can serve for two years and may be re-elected, with specific conditions for avoiding conflicts of interest [4]

Group 1 - The Shanghai Stock Exchange has announced the candidate list for the third Technology Innovation Advisory Committee, which includes 60 individuals, with a public notice period of 5 working days [1] - Notable candidates include chairpersons and executives from listed companies such as Yinjia Yao from Zhongwei Company, Ji Fan Gao from Trina Solar, Xiaolong He from China Resources Microelectronics, and Lianshan Zhang from Jiangsu Hengrui Medicine [1] - The list also features founders and CEOs from well-known technology companies, including Xingxing Wang from Yushu Technology, Bicheng Han from Qiangnao Technology, Zhihui Peng from Zhiyuan Robotics, and He Wang from Galaxy General Robotics [1] Group 2 - The complete candidate list includes various professionals from different sectors, such as environmental planning, medical innovation, and aerospace engineering [2] - Key individuals on the list include Wang Wei Dong from the PLA General Hospital, Yinjia Yao from Zhongwei Semiconductor Equipment, and Ji Fan Gao from Trina Solar [2][3] - The committee aims to enhance the technological innovation landscape in China by leveraging the expertise of these candidates [1]

Core Insights - Complement drugs are specifically designed to treat diseases related to abnormal activation or suppression of the complement system, with a complex development history that faced significant challenges until the first drug, Soliris, was approved in 2007 [1][4] - The market for complement drugs is expanding rapidly, with a projected global market size of $8.179 billion in 2024, reflecting a year-on-year growth of 23.4%, primarily driven by advancements in treatment for eye diseases [1][6] - The leading complement drugs in the market are AstraZeneca's C5 antibodies, Soliris and Ultomiris, which together are expected to account for 79.6% of total sales in 2024 [1][6][7] Industry Overview - The complement drug industry has evolved to include over ten approved drugs, utilizing various forms such as monoclonal antibodies, small molecule inhibitors, cyclic peptides, and nucleic acid aptamers, indicating a diverse technological landscape [1][4] - The expansion of indications from rare blood diseases to more common conditions signifies a maturation in the development of complement drugs, with ongoing research opening new therapeutic areas [1][4][8] Market Dynamics - The sales of Ultomiris are projected to grow significantly, from $339 million in 2019 to $3.924 billion in 2024, surpassing Soliris, which is expected to see a decline in sales by 17.7% to $2.588 billion in 2024 [7] - Domestic companies such as Heng Rui Medicine and Hai Si Ke are actively entering the complement drug market, with over ten clinical trials registered in China, primarily focusing on IgA nephropathy [1][8] Future Trends - The competition in the complement drug market is expected to intensify with the introduction of more drugs, emphasizing technological innovation and cost reduction to enhance accessibility [8] - There is a growing focus on multi-target and combination therapy strategies, which may improve treatment efficacy and reduce side effects, as well as an expansion of applications to include more rare and autoimmune diseases [8]

Core Insights - Baiyang Pharmaceutical announced a strategic investment in Tianjin Jikun Pharmaceutical, acquiring a 24% stake to secure rights to a novel drug for pulmonary fibrosis and priority purchase rights for global compound rights [1][2] Industry Overview - The respiratory disease sector is gaining attention, with recent business development (BD) transactions highlighting its potential, despite historically lower interest compared to oncology and weight loss markets [2] - Major players in the respiratory market include both domestic companies and multinational corporations like AstraZeneca, Sanofi, GSK, and Kasy, with a mix of common inhalation therapies and advanced biologics [4] Market Potential - The Chinese respiratory drug market is projected to reach approximately $12.8 billion by 2024, driven by a significant patient population, including around 45.7 million asthma patients and nearly 100 million COPD patients [4] - Recent BD transactions, such as the collaboration between Hengrui Medicine and GSK, have sparked interest in the PDE3/4 target, indicating a competitive landscape for future partnerships [2][3] Product Development - Kasy has launched a new inhalation powder for asthma treatment, representing a novel option in the market, while AstraZeneca has received approval for a biologic treatment for severe eosinophilic asthma in children [4] - The ongoing development of biologics is seen as a potential future direction for treating respiratory diseases, although inhalation therapies remain the cornerstone of treatment [5][6]

Investment Rating - The industry rating is "Positive" for the next 12 months, expecting a growth rate exceeding 10% relative to the CSI 300 index [67][79]. Core Insights - The report highlights the impressive research outcomes of Chinese pharmaceutical companies showcased at the 2025 World Lung Cancer Conference (WCLC), emphasizing the strength of innovation in the sector. It also notes that Heng Rui has further advanced its overseas licensing strategy through the NewCo model [9][67]. - The report suggests continuous monitoring of the R&D progress of Chinese pharmaceutical companies, particularly in innovative drugs and related industrial chains, benefiting from optimized procurement rules in the pharmaceutical and medical device sectors, as well as the recovery of traditional Chinese medicine and medical services due to domestic demand [9][67]. Industry News - Bai Li Tian Heng's dual-target ADC for EGFR/HER3 has shown promising results at WCLC, with a 100% overall response rate in a study involving 154 patients [18]. - BeiGene presented the latest findings from its RATIONALE studies at WCLC, demonstrating significant survival benefits for its drug in treating non-small cell lung cancer [19]. - Kangfang Biotech updated data from its HARMONi study, showing improved overall survival rates, particularly in North America [20]. Company Announcements - Heng Rui Pharma signed a licensing agreement with Braveheart Bio for the HRS-1893 project, with an upfront payment of $65 million and potential milestone payments totaling up to $1.013 billion [35]. - The new drug application for KN026 by CSPC has been accepted by the National Medical Products Administration (NMPA) [39]. - Junshi Biosciences reported positive results from its Phase III clinical trial for an anti-IL-17A monoclonal antibody [40]. Market Review - The Shanghai Composite Index rose by 2.91%, while the Shenzhen Component Index increased by 7.11%. The pharmaceutical and biological sector saw a 1.76% increase, with most sub-sectors showing positive performance [53][57]. - As of September 11, 2025, the TTM P/E ratio for the pharmaceutical and biological industry was 31.56, with a valuation premium of 148% relative to the CSI 300 [57]. Weekly Strategy - The report recommends focusing on investment opportunities in innovative drugs and medical devices, as well as sectors benefiting from domestic demand recovery, while maintaining a "Positive" industry rating [67].